BIOSYSEN (01355) plans to increase its registered capital.

BIOSYSEN (01355) announced that the company's board of directors has proposed to increase the issued share capital by adding 8 billion shares, raising the company's authorized share capital from HKD 20 million (comprising 2 billion shares of HKD 0.01 each) to HKD 100 million (comprising 10 billion shares). Upon issuance, these additional shares will rank equally in all respects with the existing shares (increase in authorized share capital). As of the date of this announcement, 1.193 billion shares have been issued, with 806.9 million shares being authorized but unissued. To address the potential growth and development of the group and provide greater flexibility for future fundraising, the board believes that increasing the authorized share capital is in the overall interest of the company and its shareholders.